Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
salbutamol
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Inhalation, Oral, Intravenous, Subcutaneous, Intramuscular
01
Overview
Salbutamol (also known as albuterol in the US) is a short-acting beta-2 adrenergic receptor agonist used primarily as a bronchodilator to relieve symptoms of asthma and chronic obstructive pulmonary disease (COPD), including bronchospasm associated with chronic bronchitis and emphysema. It acts by selectively stimulating beta-2 adrenoceptors in the smooth muscle of the airways leading to relaxation and bronchodilation. Salbutamol is more selective for pulmonary beta-2 receptors than cardiac beta-1 receptors. The drug is available in various formulations including inhalers (metered-dose aerosol and dry powder), nebulizer solutions, oral tablets/syrups and injectable forms[1][3][8]. The R-isomer of salbutamol (levalbuterol) has greater affinity for the beta-2 receptor; however most commercial preparations are racemic mixtures.
- Brand names
- VentolinAiromirAsthalinAsmatolAzmasolProAir HFAProAir DigihalerProAir RespiClickProventil HFAAccuNebSalamol
- Other names
- albuterol sulfatesalbutamol sulfatesultanol
02
Targets
ADRB2 (β2)
Beyond the preview
Go deeper on salbutamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on salbutamol.